Galapagos NV (GLPG)
NASDAQ: GLPG · Real-Time Price · USD
26.74
+0.01 (0.04%)
Feb 21, 2025, 4:00 PM EST - Market closed
Galapagos NV Revenue
In the year 2024, Galapagos NV had annual revenue of 275.65M EUR with 14.99% growth. Galapagos NV had revenue of 75.50M in the quarter ending December 31, 2024.
Revenue (ttm)
275.65M EUR
Revenue Growth
+14.99%
P/S Ratio
6.19
Revenue / Employee
245,458 EUR
Employees
1,123
Market Cap
1.77B USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 275.65M | 35.93M | 14.99% |
Dec 31, 2023 | 239.72M | -1.53M | -0.63% |
Dec 31, 2022 | 241.25M | 6.87M | 2.93% |
Dec 31, 2021 | 234.38M | -243.67M | -50.97% |
Dec 31, 2020 | 478.05M | -356.85M | -42.74% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
GLPG News
- 2 days ago - Disount To Net Cash For A Promising CAR-T Company - Seeking Alpha
- 5 days ago - Galapagos receives transparency notification and 13D filing from Tang Capital - GlobeNewsWire
- 9 days ago - Galapagos NV (GLPG) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 10 days ago - Galapagos Reports Full Year 2024 Results and Provides Fourth Quarter Business Update - GlobeNewsWire
- 4 weeks ago - Galapagos To Spin Off Innovative Medicines Business - Forbes
- 6 weeks ago - Galapagos to Unlock Shareholder Value by Declaring its Intent to Separate into Two Publicly Traded Entities - GlobeNewsWire
- 6 weeks ago - Galapagos to Present at the 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 2 months ago - Galapagos Announces Encouraging New Results from Ongoing Phase 1/2 Study of CD19 CAR T-Cell Therapy, GLPG5101, in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma - GlobeNewsWire